Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/25573
DC FieldValueLanguage
dc.contributor.authorGomes-da-Silva, Lígia C.-
dc.contributor.authorRamalho, José S.-
dc.contributor.authorLima, M. C. P. de-
dc.contributor.authorSimões, Sérgio-
dc.contributor.authorMoreira, João N.-
dc.date.accessioned2014-04-22T10:42:10Z-
dc.date.available2014-04-22T10:42:10Z-
dc.date.issued2013-
dc.identifier.urihttps://hdl.handle.net/10316/25573-
dc.description.abstractWe have previously described the development of novel sterically stabilized F3-targeted pH-sensitive liposomes, which exhibited the ability to target both cancer and endothelial cells. Herein, the therapeutic potential of those liposomes was assessed upon encapsulation of a siRNA against a well-validated molecular target, PLK1. Treatment of prostate cancer (PC3) and angiogenic endothelial (HMEC-1) cells with F3-targeted liposomes containing anti-PLK1 siRNA resulted in a significant decrease in cell viability, which was mediated by a marked PLK1 silencing, both at the mRNA and protein levels. Furthermore, pre-treatment of PC3 cells with F3-targeted liposomes containing anti-PLK1 siRNA enabled a 3-fold reduction of paclitaxel IC50 and a 2.5-fold augment of the percentage of cancer cells in G2/mitosis arrest, which ultimately culminated in cell death. Overall, the F3-targeted nanocarrier containing an anti-PLK1 siRNA might constitute a valuable system for prostate cancer treatment, either applied in a single schedule or combined with conventional chemotherapy.por
dc.description.sponsorshipThe work was supported by the Portugal–Spain capacitation program in Nanoscience and Nanotechnology (ref.: NANO/NMed-AT/0042/2007) and by Grant PEst-C/SAU/LA0001/2011.por
dc.language.isoengpor
dc.publisherElsevier B.V.por
dc.rightsopenAccesspor
dc.subjectNanotechnologypor
dc.subjectsiRNApor
dc.subjectPLK1por
dc.subjectGene silencingpor
dc.subjectPaclitaxelpor
dc.subjectProstate cancerpor
dc.titleImpact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cellspor
dc.typearticlepor
degois.publication.firstPage356por
degois.publication.lastPage364por
degois.publication.issue3 Part Apor
degois.publication.titleEuropean Journal of Pharmaceutics and Biopharmaceuticspor
dc.relation.publisherversionhttp://www.sciencedirect.com/science/article/pii/S0939641113001537#por
dc.peerreviewedYespor
dc.identifier.doi10.1016/j.ejpb.2013.04.007-
degois.publication.volume85por
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypearticle-
item.cerifentitytypePublications-
item.grantfulltextopen-
item.fulltextCom Texto completo-
item.languageiso639-1en-
crisitem.author.researchunitCQC - Coimbra Chemistry Centre-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
crisitem.author.parentresearchunitFaculty of Sciences and Technology-
crisitem.author.orcid0000-0003-0624-8819-
crisitem.author.orcid0000-0003-1844-5027-
Appears in Collections:FCTUC Ciências da Vida - Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
1-s2.0-S0939641113001537-main(1).pdf1.19 MBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

26
checked on Nov 11, 2022

WEB OF SCIENCETM
Citations 5

28
checked on May 2, 2023

Page view(s)

333
checked on Apr 16, 2024

Download(s)

475
checked on Apr 16, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.